| scholarly article | Q13442814 |
| P50 | author | Anita D'Souza | Q57018811 |
| Morie A Gertz | Q57052163 | ||
| P2093 | author name string | Craig Reeder | |
| Stephen Ansell | |||
| P2860 | cites work | Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia | Q24634360 |
| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. | Q27851888 | ||
| Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q28201685 | ||
| Risk of second cancers in Waldenström macroglobulinemia | Q28236402 | ||
| Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia | Q28237372 | ||
| How I treat Waldenström macroglobulinemia | Q28252497 | ||
| Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) | Q28281536 | ||
| Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines | Q28290236 | ||
| Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden | Q28290841 | ||
| Thalidomide and rituximab in Waldenstrom macroglobulinemia | Q28291293 | ||
| Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. | Q28297940 | ||
| Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia | Q33382030 | ||
| Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. | Q33382618 | ||
| Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia | Q33388196 | ||
| Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study | Q33389034 | ||
| Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia | Q33390926 | ||
| Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab | Q33395286 | ||
| IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. | Q33707455 | ||
| Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia | Q33711127 | ||
| Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder | Q34317497 | ||
| Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. | Q34608608 | ||
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q35116840 | ||
| Novel agents in Waldenström macroglobulinemia. | Q35429544 | ||
| Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity | Q35553334 | ||
| Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. | Q36542990 | ||
| Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia | Q36862542 | ||
| Bortezomib in relapsed or refractory Waldenström's macroglobulinemia | Q37442347 | ||
| IgM amyloidosis: clinical features in therapeutic outcomes | Q37860017 | ||
| New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. | Q37868872 | ||
| Hematopoietic cell transplantation for Waldenström macroglobulinemia. | Q37875673 | ||
| Evidence-based focused review of management of hyperviscosity syndrome | Q37965505 | ||
| Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop | Q38059720 | ||
| Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil | Q39224543 | ||
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction | Q41149988 | ||
| High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease | Q42969037 | ||
| Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs | Q43651033 | ||
| Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). | Q44023176 | ||
| Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma | Q44734725 | ||
| High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation | Q45145867 | ||
| Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia | Q45148588 | ||
| Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. | Q45915335 | ||
| International prognostic scoring system for Waldenstrom macroglobulinemia | Q46131613 | ||
| The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Stu | Q46345800 | ||
| Rituximab for the treatment of autoimmune cytopenias | Q46868815 | ||
| AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity | Q48016366 | ||
| Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study | Q48016426 | ||
| Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. | Q48972581 | ||
| Jak/Stat pathway in Waldenström's macroglobulinemia. | Q54599843 | ||
| Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide | Q57904806 | ||
| Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia | Q58050877 | ||
| AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome | Q58853160 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 295-303 | |
| P577 | publication date | 2013-05-08 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Waldenström macroglobulinaemia: the key questions | |
| P478 | volume | 162 |
| Q92139871 | Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia |
| Q34555067 | Diagnosis and management of neuropathies associated with plasma cell dyscrasias. |
| Q52868118 | Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology. |
| Q38150849 | Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models |
Search more.